Tore Saxne
131 – 140 of 247
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
No increase of severe infections in RA patients treated with TNF-blockers
2005) Annual European Congress of Rheumatology, 2005 In Annals of the Rheumatic Diseases 64(Suppl. 3). p.461-462(
- Contribution to journal › Published meeting abstract
-
Mark
Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales
(
- Contribution to journal › Letter
-
Mark
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
(
- Contribution to journal › Article
-
Mark
Changes of cartilage and bone markers after intraarticular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Prognostic laboratory markers of joint damage in rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Matrix Glycoproteins and Proteoglycans in Cartilage
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
(
- Contribution to journal › Article